Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces that it will be presenting new ...

Katie Medrano, program manager in the Office of Research and Sponsored Programs, noted that three performers (a band, Cade ...

When two massive earthquakes (magnitudes 7.7 and 7.6) devastated southern and central Turkey in February 2023, they did more ...

Auron will present data highlighting the activity of AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of neuroendocrine ...

Global sea surface temperatures in 2023–24 exceeded the previous record by an unprecedented margin. Observation-based statistical models and climate models suggest that such jumps in ocean ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer Firs ...

A landmark memorandum of understanding (MoU) was also signed between the PGIMER, Chandigarh, and the Indian Institute of ...

Jennifer McLauchlan was selected to present her research to politicians and expert judges in parliament on 11th March.

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...